Baxter International Inc.: Beat — EPS $0.58, Revenue $2.98B
Earnings BeatQ3 2026 · Pre-market
Did Baxter International Inc. (BAX) beat earnings today?
Yes, Baxter International Inc. (BAX) beat Wall Street analyst expectations for Q3 2026, reporting higher-than-expected EPS and higher-than-expected revenue.
Earnings Per Share+11.54% surprise
$0.58Actual
Expected: $0.52
vs. year ago -15.9%
Total Revenue+2.27% surprise
$2.98BActual
Expected: $2.91B
vs. year ago +5.0%
Released Oct 29 · 7:15 AM ET
Earning Report
| Metric | Q3 2026 | Q3 2025 | YoY Change % |
|---|---|---|---|
| Revenue | $2.98B | $2.83B | +5.0% |
| Revenue detail — reported lines | |||
| └─Infusion Therapies & Platforms | $1.76B | $1.67B | +5.0% |
| └─Advanced Surgery | $342.00M | $306.00M | +12.0% |
| └─Medical Products & Therapies | $2.10B | $1.98B | +6.0% |
| └─Care & Connectivity Solutions | $498.00M | $473.00M | +5.0% |
| └─Front Line Care | $308.00M | $300.00M | +3.0% |
| └─Healthcare Systems & Technologies | $806.00M | $773.00M | +4.0% |
| └─Other | $68.00M | $85.00M | -20.0% |
| Net Income | $294.00M | $(46)M | - |
| GAAP Basic EPS | $0.57 | $(0.09) | - |
| GAAP Diluted EPS | $0.57 | $(0.09) | - |
| Adj. Diluted EPS | $0.58 | $0.69 | -16.0% |
Financial Outlook / Guidance
| Metric | Next Quarter Outlook | FY 2026 Outlook |
|---|---|---|
| Reported Sales Growth | — | 4% to 5% (prev. 3% to 4%) |
| Organic Sales Growth | — | 3% to 4% (prev. 2% to 3%) |
| Adjusted EPS | — | $2.05 to $2.15 (prev. $1.95 to $2.15) |
Business Highlights
- ➤Completed a $600M cash tender offer and retired $864M of debt.
- ➤Updated the segment reporting structure beginning in Q2 2026.
- ➤Former Pharmaceuticals segment moved into Infusion Therapies & Platforms.
- ➤Infusion Systems, Drug Compounding and IV Solutions showed strength.
- ➤Global demand for Advanced Surgery products remained strong.
- ➤Care & Connectivity Solutions demand was driven by Global Surgical Solutions and Patient Support Systems.
- ➤Front Line Care delivered growth.
- ➤Baxter provides connected solutions, medical devices and advanced injectable technologies across care settings.
Management Commentary
Andrew Hider, president and CEO
“We delivered a strong third quarter, with growth across all segments and divisions globally. We continue to make steady progress stabilizing the business, strengthening the balance sheet and driving continuous improvement. Our results reinforce our confidence in this direction as we build a stronger foundation for sustainable growth and long-term value creation.”